NCT02214147View on ClinicalTrials.gov

Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 21, 2014

Primary Completion Date

April 5, 2016

Study Completion Date

July 18, 2016

Conditions
Advanced Solid TumorsRelapsed/Refractory Lymphoma
Interventions
DRUG

Alisertib

Alisertib will be supplied as enteric coated tablets.

Trial Locations (7)

Unknown

Miami

Chicago

Ann Arbor

St Louis

Dallas

Houston

San Antonio

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY